» Articles » PMID: 182897

Pathological Mechanisms in Experimental Autoimmune Myasthenia Gravis. II. Passive Transfer of Experimental Autoimmune Myasthenia Gravis in Rats with Anti-acetylcholine Recepotr Antibodies

Overview
Journal J Exp Med
Date 1976 Sep 1
PMID 182897
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Passive transfer of experimental autoimmune myasthenia gravis (EAMG) was achieved using the gamma globulin fraction and purified IgG from sera of rats immunized with Electrophus electricus (eel) acetylcholine receptor (AChR). This demonstrates the critical role of anti-AChR antibodies in impairing neuromuscular transmission in EAMG. Passive transfer of anti-AChR antibodies from rats with chronic EAMG induced signs of the acute phase of EAMG in normal recipient rats, including invasion of the motor end-plate region by mononuclear inflammatory cells. Clinical, eletrophysiological, histological, and biochemical signs of acute EAMG were observed by 24 h after antibody transfer. Recipient rats developed profound weakness and fatigability, and the posture characteristic of EAMG. Striking weight loss was attributable to dehydration. Recipient rats showed large decreases in amplitude of muscle responses to motor nerve stimulation, and repetitive nerve stimulation induced characteristic decrementing responses. End-plate potentials were not detectable in many muscle fibers, and the amplitudes of miniature end-plate potentials were reduced in the others. Passively transferred EAMG more severely affected the forearm muscles than diaphragm muscles, though neuromuscular transmission was impaired and curare sensitivity was increased in both muscles. Some AChR extracted from the muscles of rats with passively transferred EAMG was found to be complexed with antibody, and the total yield of AChR per rat was decreased. The quantitative decrease in AChR approximately paralleled in time the course of clinical and electrophysiological signs. The amount of AChR increased to normal levels and beyond at the time neuromuscular transmission was improving. The excess of AChR extractable from muscle as the serum antibody level decreased probably represented extrajunctional receptors formed in response to functional denervation caused by phagocytosis of the postsynaptic membrane by macrophages. The amount of antibody required to passively transfer EAMG was less than required to bind all AChR molecules in a rat's musculature. The effectiveness of samll amounts of antibody was probably amplified by the activation of complement and by the destruction of large areas of postsynaptic membrane by phagocytic cells. A self-sustaining autoimmune response to AChR was not provoked in animals with passively transferred EAMG.

Citing Articles

Exploring the depths of IgG4: insights into autoimmunity and novel treatments.

Unlu S, Sanchez Navarro B, Cakan E, Berchtold D, Meleka Hanna R, Vural S Front Immunol. 2024; 15:1346671.

PMID: 38698867 PMC: 11063302. DOI: 10.3389/fimmu.2024.1346671.


Pathophysiology of Childhood-Onset Myasthenia: Abnormalities of Neuromuscular Junction and Autoimmunity and Its Background.

Hayashi M Pathophysiology. 2023; 30(4):599-617.

PMID: 38133144 PMC: 10747330. DOI: 10.3390/pathophysiology30040043.


Novel pathophysiological insights in autoimmune myasthenia gravis.

Masi G, OConnor K Curr Opin Neurol. 2022; 35(5):586-596.

PMID: 35942663 PMC: 9458626. DOI: 10.1097/WCO.0000000000001088.


Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis.

Obaid A, Zografou C, Vadysirisack D, Munro-Sheldon B, Fichtner M, Roy B Neurol Neuroimmunol Neuroinflamm. 2022; 9(4).

PMID: 35473886 PMC: 9128035. DOI: 10.1212/NXI.0000000000001169.


Myasthenia Gravis: Autoantibody Specificities and Their Role in MG Management.

Lazaridis K, Tzartos S Front Neurol. 2020; 11:596981.

PMID: 33329350 PMC: 7734299. DOI: 10.3389/fneur.2020.596981.


References
1.
Brockes J, Hall Z . Synthesis of acetylcholine receptor by denervated rat diaphragm muscle. Proc Natl Acad Sci U S A. 1975; 72(4):1368-72. PMC: 432535. DOI: 10.1073/pnas.72.4.1368. View

2.
Lindstrom J, Lennon V, Seybold M, Whittingham S . Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects. Ann N Y Acad Sci. 1976; 274:254-74. DOI: 10.1111/j.1749-6632.1976.tb47691.x. View

3.
Seybold M, LAMBERT E, Lennon V, Lindstrom J . Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects. Ann N Y Acad Sci. 1976; 274:275-82. DOI: 10.1111/j.1749-6632.1976.tb47692.x. View

4.
LAMBERT E, Lindstrom J, Lennon V . End-plate potentials in experimental autoimmune myasthenia gravis in rats. Ann N Y Acad Sci. 1976; 274:300-18. DOI: 10.1111/j.1749-6632.1976.tb47694.x. View

5.
Engel A, Tsujihata M, Lindstrom J, Lennon V . The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study. Ann N Y Acad Sci. 1976; 274:60-79. DOI: 10.1111/j.1749-6632.1976.tb47676.x. View